Designed to make market research more actionable and strategically valuable, The Business Research Company’s 2026 market reports feature market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights.
Biosimulation Market To Expand At A 17.5% CAGR: Size And Growth Projections Through 2030
The biosimulation market size has seen rapid growth in recent years. It is forecast to expand from $4.98 billion in 2025 to $5.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.3%. This historical growth can be attributed to several factors, including an increase in pharmaceutical R&D activities, the rising complexity of biological systems research, the adoption of computational modeling in drug development, greater regulatory acceptance of simulation data, and the availability of advanced computing resources.
The biosimulation market size is projected to experience substantial growth over the next few years, with its valuation expected to reach $11.11 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This expansion during the forecast period is driven by factors such as an escalating demand for precision medicine modeling, increased investments in AI-driven biosimulation tools, the broadening of in silico clinical trials, a heightened focus on shortening drug development timelines, and the growing adoption of cloud-based biosimulation platforms. Furthermore, significant trends anticipated in this period include the wider embrace of model-based drug development, a rise in the use of PK and PD simulation platforms, enhanced integration of virtual clinical trials, an expansion of disease modeling applications, and a strengthened emphasis on predictive toxicology modeling.
Get Your Free Biosimulation Market Report Sample Today:
Which Factor Is Expected To Drive The Biosimulation Market Over The Forecast Period?
The worldwide increase in healthcare expenditure is anticipated to bolster the expansion of the biosimulation market throughout the forecast period. This expenditure represents the total resources allocated to healthcare goods and services, encompassing drug development, clinical trials, and medical technology. The upward trend in healthcare spending is propelled by the rising demand for advanced medical treatments, the aging global population, and enhanced investment in innovative drug development. The biosimulation market directly profits from this trend, as greater spending accelerates the adoption of computational modeling and simulation tools that facilitate virtual clinical trials and predictive disease modeling for drug development. As an illustration, the American Medical Association, a US-based national professional association, stated in April 2025 that healthcare spending climbed to US$ 4.87 trillion in 2023, marking a 7.5% year-on-year increase, equivalent to about US$ 14,570 per person. Thus, the worldwide surge in healthcare expenditure is a primary driver for the growth of the biosimulation market.
Biosimulation Market Segmentation Insights: How Is The Industry Categorized?
The biosimulation market covered in this report is segmented –
1) By Product: Software, Services
2) By Application: Drug Development, Drug Discovery, Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Academic Research Institutions, Other End Users
Subsegments:
1) By Software: Pharmacokinetics (PK) Simulation Software, Pharmacodynamics (PD) Simulation Software, Toxicology Simulation Software, Disease Modeling Software, Integrated Biosimulation Platforms
2) By Services: Consulting Services, Model Development Services, Data Analysis And Interpretation Services, Training And Support Services, Custom Simulation Services
Biosimulation Market Trends Explained: What Is Changing And Why It Matters
Major companies operating in the biosimulation market are concentrating on developing advanced solutions, such as integrated pharmacokinetic-pharmacodynamic (PK-PD) modeling platforms, with the aim of boosting drug development efficiency, improving predictive accuracy, and accelerating therapeutic decision-making. Integrated PK-PD modeling platforms refer to software systems that simulate drug behavior and its effects within virtual populations, enabling researchers to optimize dosing strategies, predict treatment outcomes, and decrease the dependence on expensive clinical trials. As an illustration, in August 2024, Certara, Inc, a US-based biosimulation and drug development company, introduced Phoenix version 8.5, an advanced platform specifically designed to streamline PK-PD modeling, population simulations, and clinical trial predictions. This software equips researchers with improved data analysis, visualization tools, and scenario testing functionalities to enhance decision-making throughout the entire drug development process. By leveraging these biosimulation capabilities, the initiative supports the development of new therapies that are faster, safer, and more cost-effective, concurrently optimizing the design of clinical studies.
Biosimulation Market Competitor Landscape: Who Are The Major Companies?
Major companies operating in the biosimulation market are Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS; Insilico Biotechnology AG; Genedata AG; Entelos Inc.; Physiomics plc; Rosa & Co. LLC.; In Silico Biosciences Inc.; INOSIM Software GmbH; LeadInvent Technologies Limited; Nuventra Pharma Sciences Inc.; Archimedes Inc.; VeriSIM Life Inc.; Compugen Inc.; Leadscope Inc.; Pharmaceutical Product Development LLC; Advanced Chemistry Development Inc.; Chemical Computing Group Inc.; Immunetrics and PPD Inc.; Instem India Private Limited; Evidera Inc.; Biomodels LLC; PhysioStim SA; Lhasa Limited; SimBioSys Inc.; Cadence Design Systems Inc.; Allucent Inc.
See The Full Biosimulation Market Report For Complete Market Sizing And Trends:
Biosimulation Market Regional Demand Analysis And Leading Geography
North America was the largest region in the biosimulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
